Background: Digital biomarkers are gaining interest as proxy markers for mental health, as they enable passive and continuous data collection. However, the association between digital biomarkers of health and anxiety, both generalized anxiety disorder and anxiety symptoms, remains unknown. Objective: This systematic review and meta-analysis examined the association between digital biomarkers of health obtained from […]
Universal Health Services buys Talkspace for $835M
Universal Health Services, which operates hospitals and mental healthcare facilities, is acquiring Talkspace for $835 million in an area closely watched for consolidation, as virtual mental health companies grapple with falling valuations despite high demand …
AbbVie, Gubra post obesity data; Regeneron obesity drug succeeds in China
Plus, news about Pfizer’s tilrekimig, Gilead-Arcellx deal, Dianthus Therapeutics, NovaBridge, Relmada Therapeutics, Ideaya, Rapport Therapeutics, Bristol Myers Squibb’s Sotyktu: 💉 AbbVie, Gubra’s long-acting amylin shows promise in early-stage trial:
How AI is turning the Iran conflict into theater
This story originally appeared in The Algorithm, our weekly newsletter on AI. To get stories like this in your inbox first, sign up here. “Anyone wanna host a get together in SF and pull this up on a 100 inch TV?” The author of that post on X was referring to an online intelligence dashboard following […]
Xenon gets Phase 3 win with epilepsy drug, setting up FDA approval filing
Xenon Pharmaceuticals’ lead drug greatly reduced the frequency of seizures in a Phase 3 epilepsy study, supporting the company’s plans to file for FDA approval in the third quarter. The drug, azetukalner, would be Xenon’ …
Hims agrees to limit compounding, ending feud with Novo Nordisk
Hims & Hers has agreed to offer Novo Nordisk’s GLP-1 obesity and diabetes treatments on its website and limit access to compounded versions. The move seemingly ends a conflict that escalated last month when the …
Bristol Myers says second CELMoD succeeds in Phase 3
Bristol Myers Squibb has claimed another success from its CELMoD program. The oral protein degrader mezigdomide cleared the Phase 3 portion of an open-label study called SUCCESSOR-2 in relapsed or refractory multiple myeloma, the company …
Incyte breaks new ground in anal cancer with EU approval
Incyte claims EU approval for Zynyz as the first systemic therapy for anal cancer, as J&J gets the nod for wider use of Akeega in prostate cancer.
Incyte receives CRL over issues at Novo’s Indiana factory
The FDA has handed Incyte a complete response letter for a label expansion of the company’s monoclonal antibody Zynyz over issues at a third-party manufacturing site in Indiana that was formerly owned by Catalent. …
RNA editing startup Tacit Therapeutics launches with $19M for brain diseases
There’s more than one way to fix a broken gene, and a new startup believes that a tool for altering large swaths of RNA code, rather than the underlying DNA, could be …
Spruce hooks a commercial chief to prep for rare disease launch
Spruce Biosciences has named Dale Hooks chief commercial officer, securing a leader with experience launching 21 products as the company heads toward a filing for its first FDA approval.
MEDAI-LLM-SUMM: a reporting checklist for medical text summarization studies using large language models
BackgroundMedical text summarization using large language models (LLMs) has reached an inflection point in 2024–2025, with adapted models demonstrating capability to match or exceed human expert performance in specific tasks. However, critical gaps persist in safety validation, evaluation frameworks, and clinical deployment readiness. A comprehensive review revealed that only 7% of studies conducted external validation […]